The pharmacist CanSino recommended this Sunday get a booster of your covid-19 vaccine six months after receiving the first dose, after a study carried out by the company, which has already been delivered to the Mexican health authority.
“The biopharmaceutical company CanSino Biologics (CanSino BIO) reports that it has obtained new, precise and conclusive results that the levels of neutralizing antibodies in its anticovid vaccine remain high – by almost 70% – in people, six months after being vaccinated with this unit dose ”, indicated the pharmacist in a statement.
In addition, pointed out that a second dose of the vaccine achieves that the levels of neutralizing antibodies are multiplied by eight.
“A second application of the CanSino vaccine does provide greater protection to those who have received it, and it is safe,” said the document.
He indicated that the studies showed that for those who received two injections of inactivated virus vaccines, a third application of the biological as a booster has generated antibody levels “several times higher than the products due to the application as a booster of other doses of inactivated virus vaccines. ”.
He reiterated that his vaccine is “highly safe that provides lasting protection -more than six months-, avoids hospitalization and death in 90% of the people to whom it is applied.”
He recalled that it continues with phase III of the clinical trials of its biological in Mexico, in which 15,000 volunteers from Mexico participate, and as soon as final results are obtained, modifications will be made related to the number of doses required of the vaccine.
So far, Mexico has received almost 13 million doses of CanSino out of a total of 35 million acquired and with this drug, the Government vaccinated all public and private educational personnel in the 32 states of the country.
Mexico has supplied a total of 71.6 million vaccines of various drugs in a country of 126 million people, although only 27.13 have a complete schedule.
In addition to CanSino, the country has committed 34.4 million doses from the American Pfizer, 79.4 million from the Anglo-Swedish AstraZeneca, 24 million from the Russian Sputnik V, 20 million from the Chinese Sinovac, 12 million from the also Chinese Sinopharm and 51.4 million from the WHO Covax platform
– .
